The FDA expands collaboration with CN Bio to investigate lung-on-a-chip model for inhaled drug evaluation applications

CN Bio, a leading developer of single- and multi-organ-on-chip microphysiological systems (MPS) that improve the accuracy and efficiency of drug discovery, today announced the U.S. Food and Drug Administration (FDA) has extended their research collaboration, for a further three years.

The scope of the research carried out with the FDA’s Center for Drug Evaluation and Research (CDER) has now been broadened to include the exploration of CN Bio’s lung-on-a-chip using the PhysioMimix™ MPS platform, to appraise the system’s use for the evaluation of inhaled drug products and assessing additional applications for CN Bio’s liver model.

The extension follows the success of CN Bio and the FDA’s initial 4-year agreement, culminating in a co-publication that demonstrated the advanced performance of the Company’s liver-on-a-chip MPS; the first co-authored, peer-reviewed article between a microphysiological system provider and a regulator1. With a plan to follow a similar process, the extended collaboration will involve studying lung microphysiological systems to obtain physiological relevant parameters for inhaled drug products. The performance of the lung microphysiological systems will be compared to traditional techniques.

Successful development and regulatory assessment of novel and generic pulmonary therapeutics can be enhanced by drug development tools that provide reliable measurements of key parameters, such as drug absorption, metabolism and permeability in the lungs.

Using MPS, complex human-relevant 3D lung models can include accurate physiological micro-architecture; co-culture of lung-specific cell types, and incorporation of innate immune cells. In doing so, researchers can create an organotypic air-liquid interface, with more utility than current approaches, for evaluating the effects of environmental toxins, consumer products, and the safety and efficacy of new inhaled medicines.

This expanded collaborative project with the world’s leading regulator, the FDA, sends a reinforcing message to the pharmaceutical sector supporting the use of organ-on-a-chip microphysiological systems. The data from our previous study fortifies the growing body of evidence demonstrating the utility of CN Bio’s platforms and encouraging the adoption of MPS into drug discovery and development workflows.

Following the co-publication, we have seen a significant increase in customer interest surrounding our liver MPS, and expect similarly exciting outcomes for this upcoming lung project.”

Dr. David Hughes, CEO, CN Bio

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    CN-Bio. (2023, March 29). The FDA expands collaboration with CN Bio to investigate lung-on-a-chip model for inhaled drug evaluation applications. News-Medical. Retrieved on May 21, 2024 from https://www.news-medical.net/news/20210505/The-FDA-expands-collaboration-with-CN-Bio-to-investigate-lung-on-a-chip-model-for-inhaled-drug-evaluation-applications.aspx.

  • MLA

    CN-Bio. "The FDA expands collaboration with CN Bio to investigate lung-on-a-chip model for inhaled drug evaluation applications". News-Medical. 21 May 2024. <https://www.news-medical.net/news/20210505/The-FDA-expands-collaboration-with-CN-Bio-to-investigate-lung-on-a-chip-model-for-inhaled-drug-evaluation-applications.aspx>.

  • Chicago

    CN-Bio. "The FDA expands collaboration with CN Bio to investigate lung-on-a-chip model for inhaled drug evaluation applications". News-Medical. https://www.news-medical.net/news/20210505/The-FDA-expands-collaboration-with-CN-Bio-to-investigate-lung-on-a-chip-model-for-inhaled-drug-evaluation-applications.aspx. (accessed May 21, 2024).

  • Harvard

    CN-Bio. 2023. The FDA expands collaboration with CN Bio to investigate lung-on-a-chip model for inhaled drug evaluation applications. News-Medical, viewed 21 May 2024, https://www.news-medical.net/news/20210505/The-FDA-expands-collaboration-with-CN-Bio-to-investigate-lung-on-a-chip-model-for-inhaled-drug-evaluation-applications.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
The FDA further expands collaboration with CN Bio to evaluate the PhysioMimix Multi-organ microphysiological system